CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer. | Profiles RNS

RCMI Coordinating Center (RCMI CC)

CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer.

Agrawal S, Dwivedi M, Ahmad H, Chadchan SB, Arya A, Sikandar R, Kaushik S, Mitra K, Jha RK, Dwivedi AK. CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer. Nanomedicine. 2018 02; 14(2):327-337.

View in: PubMed

authors with profiles

Rajesh Jha, PhD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support